ABVX
ABIVAX Société Anonyme
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
88.46
▼ 3.27 (3.56%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
86.82
Prev close
91.73
Day high
93.67
Day low
87.83
Volume
2.00M
Market cap
$7.70B
P/E (TTM)
—
52W range
69.81 – 148.83
Day trading desk
Gap from prior close
-5.35%
Prior close 91.73
VWAP
88.80
-0.38% from price
Relative volume
3.42×
Unusually busy
Session range
8.86%
86.82 – 94.52
Position in range
21%
Near session low
ATR (14D)
4.55
5.14% of price
Prior day high
92.61
PDH
Prior day low
89.40
PDL
Bid / ask spread
—
Quote not published
Session volume
3.71M
Avg 1.08M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.44%
-12.4%
1M
-23.15%
-24.3%
3M
-36.32%
-40.8%
6M
-24.26%
-42.4%
YTD
-34.58%
-48.8%
1Y
+5.12%
-11.3%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ABVX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$7.70B
Enterprise value$6.64B
Revenue (TTM)$4.67M
Gross profit$4.67M
EBITDA$-291.55M
Net income$-401.22M
EPS (TTM)$-5.84
Free cash flow$-125.90M
Total cash$402.38M
Total debt$1.21M
Book value / share$5.16
Shares outstanding87.27M
Float69.03M
Short % of float7.95%
Dividend yield0.00%
Beta (5Y)-0.23
Valuation & profitability ratios
Trailing P/E—
Forward P/E-22.73
PEG ratio—
Price / sales—
Price / book17.08
EV / revenue1,422.51
EV / EBITDA-22.78
Gross margin100.00%
Operating margin-8617.93%
Profit margin0.00%
Return on equity-252.35%
Return on assets-62.88%
Debt / equity0.33
Current ratio5.97
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | — | — | $50.76M | $45.52M | — |
| Gross profit | — | — | — | -$50.76M | -$45.52M | — |
| Research & development | $177.76M | $146.53M | $103.18M | $48.30M | — | +21.3% |
| Selling, general & admin | $72.86M | $38.90M | $28.82M | $7.49M | — | +87.3% |
| Total operating expense | $246.06M | $172.98M | $127.38M | $51.20M | — | +42.2% |
| Operating income | -$246.06M | -$172.98M | -$127.38M | -$51.20M | — | -42.2% |
| Net interest income | -$52.49M | -$5.93M | -$9.51M | -$5.27M | — | -784.9% |
| Pre-tax income | -$330.25M | -$176.24M | -$147.74M | -$60.74M | — | -87.4% |
| Tax provision | $5.85M | $0 | $0 | $0 | — | — |
| Net income | -$336.10M | -$176.24M | -$147.74M | -$60.74M | — | -90.7% |
| Net income to common | -$336.10M | -$176.24M | -$147.74M | -$60.74M | — | -90.7% |
| Basic EPS | -4.83 | -2.78 | -3.43 | -3.18 | — | -73.6% |
| Diluted EPS | -4.83 | -2.78 | -3.43 | -3.18 | — | -73.6% |
| EBIT | -$301.77M | -$163.81M | -$133.91M | -$53.80M | — | -84.2% |
| EBITDA | -$300.70M | -$162.71M | -$133.21M | -$53.31M | — | -84.8% |
| Basic shares | 69.53M | 63.35M | 43.07M | 19.09M | — | +9.8% |
| Diluted shares | 69.53M | 63.35M | 43.07M | 19.09M | — | +9.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $516.68M | $144.22M | $251.94M | $26.95M | — | +258.3% |
| Cash & short-term investments | $530.38M | $144.22M | $260.99M | $26.95M | — | +267.8% |
| Accounts receivable | — | — | — | — | $1.47M | — |
| Inventory | — | — | — | — | $4.00M | — |
| Total current assets | $551.24M | $170.67M | $285.97M | $36.18M | — | +223.0% |
| Property, plant & equipment | $2.09M | $2.67M | $877.00K | $1.59M | — | -21.5% |
| Goodwill & intangibles | $25.02M | $25.02M | $25.02M | $25.03M | — | -0.0% |
| Total assets | $584.34M | $205.23M | $327.06M | $75.54M | — | +184.7% |
| Total current liabilities | $63.02M | $92.83M | $88.11M | $51.46M | — | -32.1% |
| Current debt | — | $42.84M | $30.88M | $29.49M | $10.06M | — |
| Long-term debt | — | $52.16M | $26.62M | $8.29M | $34.61M | — |
| Total debt | $1.86M | $97.36M | $58.04M | $39.16M | — | -98.1% |
| Total liabilities | $129.14M | $164.64M | $131.05M | $68.36M | — | -21.6% |
| Retained earnings | -$738.48M | -$438.88M | -$282.95M | -$143.51M | — | -68.3% |
| Shareholder equity | $455.20M | $40.58M | $196.01M | $7.19M | — | +1,021.6% |
| Working capital | $488.22M | $77.84M | $197.86M | -$15.28M | — | +527.2% |
| Net tangible assets | $430.18M | $15.56M | $170.99M | -$17.84M | — | +2,664.8% |
| Shares issued | 78.54M | 63.35M | 62.93M | 22.30M | — | +24.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$336.10M | -$176.24M | -$147.74M | -$60.74M | -90.7% |
| Depreciation & amortisation | $1.07M | $1.10M | $707.00K | $485.00K | -2.5% |
| Stock-based compensation | $35.40M | $20.22M | $8.18M | -$1.16M | +75.0% |
| Change in working capital | $3.65M | $1.42M | $21.27M | -$2.00M | +156.6% |
| Operating cash flow | -$161.13M | -$154.07M | -$97.13M | -$53.94M | -4.6% |
| Capital expenditure | -$142.00K | -$643.00K | -$265.00K | -$323.00K | +77.9% |
| Investing cash flow | -$8.19M | $15.76M | -$8.10M | -$12.03M | -152.0% |
| Dividends paid | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $547.31M | $28.21M | $335.29M | $32.21M | +1,840.3% |
| Free cash flow | -$161.27M | -$154.72M | -$97.39M | -$54.26M | -4.2% |
| End cash position | $516.68M | $144.22M | $251.94M | $26.95M | +258.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $58.34M | $49.54M | $44.40M | $55.42M | $38.65M | — | +17.7% |
| Selling, general & admin | $26.98M | $8.03M | $27.69M | $27.34M | $8.94M | — | +235.9% |
| Total operating expense | $84.11M | $56.23M | $71.65M | $80.71M | $46.50M | — | +49.6% |
| Operating income | -$84.11M | -$56.23M | -$71.65M | -$80.71M | -$46.50M | — | -49.6% |
| Net interest income | $2.69M | $1.50M | $1.22M | -$49.14M | -$297.00K | — | +79.6% |
| Pre-tax income | -$123.51M | -$48.24M | -$76.11M | -$153.36M | -$48.41M | — | -156.0% |
| Tax provision | -$6.08M | $228.00K | $5.85M | $0 | $0 | — | -2,764.9% |
| Net income | -$117.43M | -$48.47M | -$81.96M | -$153.36M | -$48.41M | — | -142.3% |
| Net income to common | -$117.43M | -$48.47M | -$81.96M | -$153.36M | -$48.41M | — | -142.3% |
| Basic EPS | -1.47 | -0.61 | — | -2.10 | -0.76 | -0.83 | -141.0% |
| Diluted EPS | -1.47 | -0.61 | — | -2.10 | -0.76 | -0.83 | -141.0% |
| EBIT | -$122.78M | -$45.70M | -$60.84M | -$149.15M | -$44.89M | — | -168.7% |
| EBITDA | -$122.40M | -$45.33M | -$60.56M | -$148.87M | -$44.64M | — | -170.0% |
| Basic shares | 79.65M | 78.96M | — | 72.94M | 63.44M | 63.38M | +0.9% |
| Diluted shares | 79.65M | 78.96M | — | 72.94M | 63.44M | 63.38M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $387.99M | $477.42M | $516.68M | $589.70M | $60.95M | — | -18.7% |
| Cash & short-term investments | $410.68M | $491.55M | $530.38M | $589.70M | $60.95M | — | -16.5% |
| Total current assets | $427.62M | $513.22M | $551.24M | $619.29M | $86.10M | — | -16.7% |
| Property, plant & equipment | $1.52M | $1.78M | $2.09M | $1.91M | $2.16M | — | -14.5% |
| Goodwill & intangibles | $25.02M | $25.02M | $25.02M | $25.02M | $25.02M | — | 0.0% |
| Total assets | $462.21M | $547.14M | $584.34M | $652.05M | $119.64M | — | -15.5% |
| Total current liabilities | $71.69M | $62.23M | $63.02M | $78.76M | $112.35M | — | +15.2% |
| Current debt | — | — | — | $28.46M | $47.91M | $43.43M | — |
| Long-term debt | — | — | — | $15.88M | $34.78M | $47.00M | — |
| Total debt | $1.21M | $1.45M | $1.86M | $45.89M | $84.57M | — | -16.2% |
| Total liabilities | $95.94M | $117.55M | $129.14M | $140.81M | $167.92M | — | -18.4% |
| Retained earnings | -$864.96M | -$764.31M | -$738.48M | -$669.81M | -$528.60M | — | -13.2% |
| Shareholder equity | $366.27M | $429.59M | $455.20M | $511.24M | -$48.28M | — | -14.7% |
| Working capital | $355.94M | $450.99M | $488.22M | $540.53M | -$26.25M | — | -21.1% |
| Net tangible assets | $341.24M | $404.57M | $430.18M | $486.21M | -$73.31M | — | -15.7% |
| Shares issued | 79.82M | 79.29M | 78.54M | 77.83M | 63.47M | — | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$117.43M | -$48.47M | -$81.96M | -$153.36M | -$48.41M | — | -142.3% |
| Depreciation & amortisation | $374.00K | $367.00K | $276.00K | $272.00K | $251.00K | — | +1.9% |
| Stock-based compensation | $16.80M | $22.61M | $12.90M | $11.48M | $6.33M | — | -25.7% |
| Change in working capital | $1.24M | -$4.97M | -$9.73M | -$2.08M | $6.45M | — | +124.9% |
| Operating cash flow | -$51.99M | -$50.52M | -$23.23M | -$71.28M | -$33.34M | — | -2.9% |
| Capital expenditure | -$112.00K | -$54.00K | -$87.00K | — | -$19.00K | -$44.00K | -107.4% |
| Investing cash flow | $971.00K | $495.00K | -$12.74M | $3.28M | $187.00K | — | +96.2% |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | — | — |
| Financing cash flow | -$39.35M | $73.00K | -$39.55M | $603.46M | -$8.77M | — | -54,002.7% |
| Free cash flow | -$52.10M | -$50.57M | -$23.32M | -$71.28M | -$33.36M | — | -3.0% |
| End cash position | $387.99M | $477.42M | $516.68M | $589.70M | $60.95M | — | -18.7% |
Options analytics
Put / call volume
0.33
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
70.00
-20.7% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
1.53K
Contracts, this expiry
Put volume
507
Contracts, this expiry
Heaviest call OI
90.00
0 contracts
Heaviest put OI
70.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.86 | -1.69 | -97.0% |
| Mar 2026 | -0.81 | -0.71 | +12.8% |
| Dec 2025 | -1.05 | -1.18 | -13.1% |
| Sep 2025 | -0.79 | -2.47 | -214.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.90 | 4 | $691.61K | -66.2% |
| Next quarter | -0.90 | 4 | $701.19K | +49.2% |
| Current year | -4.24 | 6 | $3.99M | -13.3% |
| Next year | -3.88 | 7 | $71.87M | +1,702.8% |
Analyst targets & ownership
Mean target$164.00
High target$181.00
Low target$142.00
Implied upside85.39%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy4 / 8
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions71.73%
Institutions holding359
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
94.24
-6.13% from price
SMA 20
101.63
-13.20% from price
SMA 50
112.75
-21.75% from price
SMA 100
115.35
-23.31% from price
SMA 200
117.63
-25.00% from price
EMA 12
96.18
-8.02% from price
EMA 26
102.58
-13.77% from price
EMA 50
108.76
-18.67% from price
RSI (14)
30.2
Neutral
MACD (12,26,9)
-6.40
Hist -0.57
ATR (14)
4.55
5.15% of price
Realised vol 30D
47.9%
Annualised
Bollinger upper
119.99
20, 2σ
Bollinger lower
83.27
20, 2σ
50 / 200 cross
Death
112.75 vs 117.63
Trend bias
Below 200
-25.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.92
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
47.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-50.1%
Peak to trough
Max drawdown 5Y
-67.5%
Peak to trough
ATR 14
4.55
5.15% of price
Beta (reported)
-0.23
5Y monthly, from filing
Short interest
Shares short
6.86M
Prior 6.00M
Change vs prior
+14.3%
Shorts adding
% of float
7.95%
Normal
% of shares out
7.86%
Against total outstanding
Days to cover
6.8
Crowded exit
Float
69.03M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Sep 22, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Sep 22, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 10, 26 | Goldman Sachs | INITIATED | — | Buy |
| Sep 5, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 9, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 2, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 1, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jun 30, 26 | Jefferies | UPGRADE | Hold | Buy |
| Jun 30, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Jun 30, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Jun 30, 26 | BTIG | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-21
Corporate Changes & Voting Matters
6-K · 2026-07-02
Corporate Changes & Voting Matters
6-K · 2026-06-29
Corporate Changes & Voting Matters
6-K · 2026-06-02
Corporate Changes & Voting Matters
6-K · 2026-05-22
Corporate Changes & Voting Matters
6-K · 2026-05-20
Corporate Changes & Voting Matters
6-K · 2026-05-07
Corporate Changes & Voting Matters
6-K · 2026-04-20
Headlines
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
GlobeNewswire · 6d ago
ABIVAX Société Anonyme (ENXTPA:ABVX) Just Gave Investors Something To Think About
Simply Wall St. · 10d ago
ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers
Simply Wall St. · 10d ago
ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?
Insider Monkey · 11d ago
Wedbush Cuts Price Target on Abivax to $118 From $160, Keeps Neutral Rating
MT Newswires · 15d ago
Abivax Says Chris Rabbat to Succeed Fabio Cataldi as Chief Medical Officer
MT Newswires · 15d ago
Abivax Presents Business Updates and First Half 2026 Financial Results
GlobeNewswire · 15d ago
4 Biotech Stocks to Watch as Potential Takeover Targets
Zacks · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.